Correlation between hematological parameters and PET/CT metabolic parameters in patients with head and neck cancer.

Fluorodeoxyglucose F18 / metabolism Head and Neck Neoplasms / diagnostic imaging Humans Inflammation Positron Emission Tomography Computed Tomography / methods Prognosis Squamous Cell Carcinoma of Head and Neck / diagnostic imaging Tumor Microenvironment
Head and neck NLR PET PLR Radiotherapy

Journal

Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111

Informations de publication

Date de publication:
13 Aug 2022
Historique:
received: 28 04 2022
accepted: 26 07 2022
entrez: 13 8 2022
pubmed: 14 8 2022
medline: 17 8 2022
Statut: epublish

Résumé

Systemic inflammation is predictive of the overall survival in cancer patients and is related to the density of immune cells in the tumor microenvironment of cancer, which in turn correlates with A retrospective review of consecutive patients with HNSCC with a pretreatment PET/CT was performed. NLR and PLR were computed using complete blood counts measured within 10 days before the start of any treatment. The correlation between NLR and PLR with PET/CT-MPs was evaluated with Spearman's rho test. Seventy-one patients were analyzed. Overall survival (OS) at 1, 2, and 3 years was 86%, 76%, and 68%. PLR was found to be correlated with MTV (rho = 0.26, P = .03) and TLG (rho = 0.28, P = .02) but not with maximum SUV or mean SUV. There was no correlation between NLR and the analyzed PET/CT-MPs. TLG was associated with worse survival in uni- and multivariable analysis, but no other PET/CT-MPs were associated with either OS or disease-specific survival (DSS). NLR and PLR were associated with OS and DSS on uni- and multivariable analysis. In patients with HNSCC before any treatment such as definitive radio (chemo)therapy or oncologic surgery followed by adjuvant RT, baseline PLR correlated with MTV and TLG but not with SUV. NLR was not correlated with any PET/CT-MPs analyzed in our study. Confirmatory studies are needed, and a potential interaction between tumor microenvironment, host inflammation, and FDG-PET/CT measures warrants further investigation.

Sections du résumé

BACKGROUND BACKGROUND
Systemic inflammation is predictive of the overall survival in cancer patients and is related to the density of immune cells in the tumor microenvironment of cancer, which in turn correlates with
METHODS METHODS
A retrospective review of consecutive patients with HNSCC with a pretreatment PET/CT was performed. NLR and PLR were computed using complete blood counts measured within 10 days before the start of any treatment. The correlation between NLR and PLR with PET/CT-MPs was evaluated with Spearman's rho test.
RESULTS RESULTS
Seventy-one patients were analyzed. Overall survival (OS) at 1, 2, and 3 years was 86%, 76%, and 68%. PLR was found to be correlated with MTV (rho = 0.26, P = .03) and TLG (rho = 0.28, P = .02) but not with maximum SUV or mean SUV. There was no correlation between NLR and the analyzed PET/CT-MPs. TLG was associated with worse survival in uni- and multivariable analysis, but no other PET/CT-MPs were associated with either OS or disease-specific survival (DSS). NLR and PLR were associated with OS and DSS on uni- and multivariable analysis.
CONCLUSIONS CONCLUSIONS
In patients with HNSCC before any treatment such as definitive radio (chemo)therapy or oncologic surgery followed by adjuvant RT, baseline PLR correlated with MTV and TLG but not with SUV. NLR was not correlated with any PET/CT-MPs analyzed in our study. Confirmatory studies are needed, and a potential interaction between tumor microenvironment, host inflammation, and FDG-PET/CT measures warrants further investigation.

Identifiants

DOI: 10.1186/s13014-022-02112-4 PMID: 35964056 PMC: PMC9375277
pubmed: 35964056
doi: 10.1186/s13014-022-02112-4
pii: 10.1186/s13014-022-02112-4
pmc: PMC9375277
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

141

Informations de copyright

© 2022. The Author(s).

Références

Ann Surg Treat Res. 2015 Aug;89(2):81-6
pubmed: 26236697
Radiother Oncol. 2018 Nov;129(2):409-414
pubmed: 30249348
CA Cancer J Clin. 2017 Mar;67(2):122-137
pubmed: 28128848
Oncology. 2019;96(1):8-13
pubmed: 30212829
J Thorac Oncol. 2011 Apr;6(4):824-33
pubmed: 21173711
J Natl Cancer Inst. 2022 Apr 11;114(4):609-617
pubmed: 34850048
Radiat Oncol. 2015 Jan 17;10:20
pubmed: 25595218
Int J Clin Oncol. 2019 Feb;24(2):168-178
pubmed: 30109543
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Appl Immunohistochem Mol Morphol. 2016 Jul;24(6):392-7
pubmed: 27333219
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2122-2138
pubmed: 29948105
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Res. 2015 Jun 1;75(11):2232-42
pubmed: 25858148
Lancet Oncol. 2016 Apr;17(4):440-451
pubmed: 26936027
BMC Cancer. 2019 Feb 12;19(1):141
pubmed: 30755184
Nat Rev Clin Oncol. 2017 Jun;14(6):365-379
pubmed: 28094262
Br J Cancer. 2013 Jul 9;109(1):147-53
pubmed: 23778526
Ann Nucl Med. 2015 Dec;29(10):906-10
pubmed: 26296613
Quant Imaging Med Surg. 2019 Mar;9(3):440-452
pubmed: 31032191
J Thorac Cardiovasc Surg. 2008 Apr;135(4):823-9
pubmed: 18374762
Oncotarget. 2017 May 9;8(19):32171-32189
pubmed: 28418870
Oncol Rep. 2006 Aug;16(2):329-34
pubmed: 16820911
Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):137-145
pubmed: 29960819
Ann Nucl Med. 2019 Jan;33(1):32-38
pubmed: 30218280
Histopathology. 2018 Sep;73(3):500-509
pubmed: 29768723
Radiat Oncol. 2014 Nov 27;9:263
pubmed: 25479896
Lancet Oncol. 2019 Aug;20(8):e404-e416
pubmed: 31364593
Lancet Oncol. 2021 Apr;22(4):450-462
pubmed: 33794205
Breast Cancer Res. 2014 Nov 29;16(6):488
pubmed: 25432519
J Clin Oncol. 2016 Nov 10;34(32):3838-3845
pubmed: 27646946
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Eur J Cancer. 2011 Nov;47(17):2633-41
pubmed: 21724383
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Oncol Lett. 2018 Feb;15(2):1664-1672
pubmed: 29399193
Radiat Oncol. 2012 Oct 22;7:175
pubmed: 23088283
Gastric Cancer. 2017 Jul;20(4):602-611
pubmed: 27665104
Indian J Otolaryngol Head Neck Surg. 2018 Jun;70(2):175-179
pubmed: 29977836
Eur Arch Otorhinolaryngol. 2017 Mar;274(3):1683-1690
pubmed: 27933385
Strahlenther Onkol. 2015 Jul;191(7):566-72
pubmed: 25575976
Radiat Oncol. 2018 Nov 6;13(1):216
pubmed: 30400969
Gynecol Oncol. 2017 Jun;145(3):584-594
pubmed: 28222899
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1127-1136
pubmed: 31502013
Colorectal Dis. 2018 May;20(5):407-415
pubmed: 29178362
Nucl Med Commun. 2019 Oct;40(10):1051-1059
pubmed: 31365497
J Oral Pathol Med. 2018 Apr;47(4):353-358
pubmed: 29406591
PET Clin. 2020 Oct;15(4):453-461
pubmed: 32739048
Cancer Treat Rev. 2017 Jul;58:1-13
pubmed: 28602879
Breast Cancer Res. 2017 Jan 5;19(1):2
pubmed: 28057046
Biochim Biophys Acta. 2016 Mar;1863(3):392-400
pubmed: 26193075
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
BMC Cancer. 2018 Apr 4;18(1):383
pubmed: 29618336
World J Gastroenterol. 2014 Apr 28;20(16):4586-96
pubmed: 24782611

Auteurs

Beat Bojaxhiu (B)

Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, 3010, Bern, Switzerland. beat.bojaxhiu@insel.ch.
Department of Radiation Oncology, Stadtspital Triemli, Zurich, Switzerland. beat.bojaxhiu@insel.ch.

Dubravko Sinovcic (D)

Department of Radiation Oncology, Stadtspital Triemli, Zurich, Switzerland.

Olgun Elicin (O)

Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, 3010, Bern, Switzerland.

Arnoud J Templeton (AJ)

Department of Medical Oncology, St. Claraspital Basel and Faculty of Medicine, University of Basel, Basel, Switzerland.

Mohamed Shelan (M)

Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, 3010, Bern, Switzerland.

Jan Wartenberg (J)

Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Ian Alberts (I)

Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Axel Rominger (A)

Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Daniel M Aebersold (DM)

Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, 3010, Bern, Switzerland.

Kathrin Zaugg (K)

Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, 3010, Bern, Switzerland.
Department of Radiation Oncology, Stadtspital Triemli, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Glucides › Désoses › Désoxyglucose › Fluorodésoxyglucose F18 › Correlation between hematological parameters...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › Correlation between hematological parameters...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Correlation between hematological parameters...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Correlation between hematological parameters...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Tomographie par émission de positons couplée à la tomodensitométrie › Correlation between hematological parameters...
questionsmedicales.fr › Diagnostic › Pronostic › Correlation between hematological parameters...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › Carcinome épidermoïde de la tête et du cou › Correlation between hematological parameters...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › Correlation between hematological parameters...